Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name. In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology. Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services. The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia. Swift Limited was founded in 1983 and is based in Chandigarh, India. As of August 8, 2025, Ind-Swift Limited operates as a subsidiary of Ind-Swift Laboratories Limited.
Show more...
CEO
Mr. Sanjeev Rai Mehta BSc
국가
인도
ISIN
INE788B01028
상장
0 Comments
생각을 공유하기
FAQ
오늘 Ind-Swift 주가는 얼마인가요?▼
INDSWFTLTD.NSE의 현재 가격은 ₹15.71 INR이며, 지난 24시간 동안 +0% 상승했습니다. 차트에서 Ind-Swift 주가 흐름을 더 자세히 살펴보세요.
Ind-Swift의 주식 심볼은 무엇인가요?▼
거래소에 따라 주식 심볼이 다를 수 있습니다. 예를 들어, 거래소에서는 Ind-Swift 주식이 INDSWFTLTD.NSE 심볼로 거래됩니다.
Ind-Swift의 지난해 매출은 얼마였나요?▼
Ind-Swift의 지난해 매출은 4.93BINR입니다.
Ind-Swift의 지난해 순이익은 얼마였나요?▼
INDSWFTLTD.NSE의 지난해 순이익은 142.31MINR입니다.
Ind-Swift는 배당금을 지급하나요?▼
네, INDSWFTLTD.NSE의 배당금은 연간마다 지급됩니다. 최근 1주당 배당금은 0.4 INR였습니다. 현재 배당수익률(FWD)%은 0%입니다.